X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26302) 26302
Book Chapter (277) 277
Dissertation (100) 100
Newspaper Article (72) 72
Book / eBook (45) 45
Magazine Article (11) 11
Conference Proceeding (2) 2
Publication (2) 2
Web Resource (2) 2
Government Document (1) 1
Newsletter (1) 1
Reference (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18693) 18693
animals (10511) 10511
biochemistry & molecular biology (8066) 8066
cancer (6549) 6549
oncology (5833) 5833
molecular targeted therapy (5169) 5169
female (4625) 4625
male (4061) 4061
research (3861) 3861
cell biology (3844) 3844
mice (3723) 3723
review (3469) 3469
proteins (3423) 3423
care and treatment (3333) 3333
health aspects (3315) 3315
pharmacology & pharmacy (3298) 3298
gene expression (2887) 2887
biology (2869) 2869
apoptosis (2826) 2826
chemotherapy (2773) 2773
tumors (2698) 2698
medicine, research & experimental (2670) 2670
medicine (2546) 2546
antineoplastic agents - therapeutic use (2521) 2521
expression (2490) 2490
molecular biology (2405) 2405
analysis (2351) 2351
chemistry, multidisciplinary (2257) 2257
treatment outcome (2256) 2256
mutation (2255) 2255
signal transduction (2117) 2117
genetic aspects (2076) 2076
kinases (2050) 2050
genetics & heredity (2024) 2024
molecular medicine (1957) 1957
inflammation (1921) 1921
middle aged (1906) 1906
therapy (1891) 1891
cell line, tumor (1875) 1875
research article (1863) 1863
cancer therapies (1843) 1843
metastasis (1812) 1812
biotechnology & applied microbiology (1765) 1765
pharmacology (1740) 1740
clinical trials (1710) 1710
chemistry (1640) 1640
adult (1639) 1639
aged (1637) 1637
immunology (1632) 1632
antineoplastic agents - pharmacology (1620) 1620
immunotherapy (1607) 1607
genetics (1599) 1599
multidisciplinary sciences (1582) 1582
physiological aspects (1577) 1577
drug therapy (1574) 1574
neoplasms - drug therapy (1564) 1564
science (1530) 1530
risk factors (1499) 1499
prognosis (1492) 1492
patients (1467) 1467
signal transduction - drug effects (1434) 1434
hematology (1424) 1424
medical research (1418) 1418
in-vitro (1409) 1409
biomedicine (1399) 1399
molecular targeted therapy - methods (1396) 1396
in-vivo (1393) 1393
studies (1358) 1358
development and progression (1345) 1345
drugs (1344) 1344
breast cancer (1339) 1339
biomarkers (1322) 1322
oxidative stress (1311) 1311
cells (1299) 1299
clinical trials as topic (1277) 1277
life sciences (1276) 1276
stem cells (1248) 1248
antineoplastic agents - adverse effects (1236) 1236
drug discovery (1229) 1229
disease models, animal (1221) 1221
rodents (1195) 1195
medicine & public health (1192) 1192
metabolism (1188) 1188
activation (1174) 1174
disease (1163) 1163
toxicity (1156) 1156
cancer research (1153) 1153
genes (1134) 1134
deoxyribonucleic acid--dna (1098) 1098
survival (1092) 1092
nanoparticles (1070) 1070
drug design (1069) 1069
inhibition (1058) 1058
usage (1057) 1057
cytokines (1054) 1054
angiogenesis (1053) 1053
double-blind (1052) 1052
rats (1042) 1042
antineoplastic combined chemotherapy protocols - therapeutic use (1004) 1004
drug delivery systems (1004) 1004
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (7) 7
Media Commons - Microtexts (3) 3
Online Resources - Online (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
UofT at Mississauga - Stacks (2) 2
Sunnybrook Health Sciences Centre - Online (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26624) 26624
Japanese (162) 162
German (72) 72
French (51) 51
Chinese (14) 14
Spanish (11) 11
Dutch (9) 9
Russian (8) 8
Hungarian (6) 6
Norwegian (5) 5
Polish (5) 5
Italian (3) 3
Portuguese (3) 3
Croatian (2) 2
Czech (1) 1
Danish (1) 1
Hebrew (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1324 - 1334
Journal Article
European urology, ISSN 0302-2838, 2015, Volume 68, Issue 2, pp. 228 - 235
Abstract Background Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic... 
Urology | Metastatic | Abiraterone | Prostate cancer | Cabazitaxel | ENZALUTAMIDE MDV3100 | CROSS-RESISTANCE | ANTITUMOR-ACTIVITY | CHEMOTHERAPY | PACLITAXEL | ANTIANDROGEN | UROLOGY & NEPHROLOGY | ABIRATERONE ACETATE | INCREASED SURVIVAL | RESISTANT PROSTATE-CANCER | CASTRATION-RESISTANT | Phenylthiohydantoin - adverse effects | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Receptors, Androgen - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Molecular Targeted Therapy | Prostatic Neoplasms, Castration-Resistant - pathology | Dose-Response Relationship, Drug | Taxoids - therapeutic use | Receptors, Androgen - drug effects | Time Factors | Aged, 80 and over | Kallikreins - blood | Retrospective Studies | France | Taxoids - adverse effects | Cell Survival - drug effects | Androstenes - adverse effects | Kaplan-Meier Estimate | Androstenes - therapeutic use | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Disease-Free Survival | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | Prostatic Neoplasms, Castration-Resistant - mortality | Androgen Antagonists - adverse effects
Journal Article
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 02/2011, Volume 16, Issue S2, pp. 32 - 44
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 4, pp. 736 - 744
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription... 
Dermatology | JAK-STAT | psoriasis | baricitinib | vitiligo | atopic dermatitis | JAK inhibitor | ruxolitinib | alopecia areata | tofacitinib | RHEUMATOID-ARTHRITIS | OCLACITINIB APOQUEL(R) | OPEN-LABEL | DERMATOLOGY | LONG-TERM EXTENSION | PHASE 2B TRIAL | ALOPECIA-AREATA | ATOPIC-DERMATITIS | JANUS KINASE INHIBITOR | PLAQUE PSORIASIS | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Dermatitis, Atopic - enzymology | Humans | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Vitiligo - drug therapy | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Psoriasis - drug therapy | Vitiligo - enzymology | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Clinical Trials as Topic | Dermatologic Agents - classification | Janus Kinases - antagonists & inhibitors | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Medical colleges | Psoriasis | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pharmaceutical industry | Tyrosine | Interleukins | Interferon | Biological response modifiers | T cells | Tofacitinib
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2011, Volume 29, Issue 18, pp. 2493 - 2498
Journal Article
Clinical microbiology and infection, ISSN 1198-743X, 2018, Volume 24, Issue Suppl 2, pp. S95 - S107
...) Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies... 
Infection | Pembrolizumab | Alefacept | Fingolimod | Natalizumab | Ipilimumab | Nivolumab | Vedolizumab | Proteasome inhibitors | Progressive multifocal leukoencephalopathy | MULTIPLE-MYELOMA | INFECTIOUS DISEASES | JC VIRUS | MICROBIOLOGY | MONOCLONAL-ANTIBODY | CEREBROSPINAL-FLUID | ANTI-PD-1 ANTIBODY | ADVANCED MELANOMA | VARICELLA-ZOSTER-VIRUS | HERPES-ZOSTER | PNEUMOCYSTIS-JIROVECII PNEUMONIA | Antibodies, Monoclonal, Humanized - adverse effects | Leukoencephalopathy, Progressive Multifocal - therapy | Molecular Targeted Therapy - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Biological Therapy - methods | Communicable Diseases - therapy | Humans | Natalizumab - adverse effects | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Genes, cdc - drug effects | Clinical Trials as Topic | Cell Adhesion - drug effects | Proteasome Inhibitors - adverse effects | Consensus | Proteasome Inhibitors - therapeutic use | Receptors, Lysosphingolipid - drug effects | Biological Therapy - adverse effects | Natalizumab - therapeutic use | Immunocompromised Host | CTLA-4 Antigen - antagonists & inhibitors | Molecular Targeted Therapy - methods | pembrolizumab | vedolizumab | infection | nivolumab | progressive multifocal leukoencephalopathy | fingolimod | ipilimumab | proteasome inhibitors | alefacept | natalizumab
Journal Article
Journal Article